Patents Assigned to Impel NeuroPharma Inc.
-
Patent number: 11278492Abstract: Methods are provided for acute treatment of agitation, including agitation in patients with schizophrenia or bipolar disorder, comprising administering to a subject with agitation an effective dose of a dry pharmaceutical composition comprising olanzapine, wherein the dose is administered by an intranasal delivery device that provides, following intranasal administration, (a) a mean peak plasma olanzapine concentration (Cmax) of at least 30 ng/mL, with (b) a mean time to Cmax (Tmax) of olanzapine of less than 0.5 hours. Dry pharmaceutical compositions and devices suitable for intranasal delivery of olanzapine are provided.Type: GrantFiled: January 4, 2019Date of Patent: March 22, 2022Assignee: Impel Neuropharma, Inc.Inventors: John D. Hoekman, Kelsey H. Satterly, Inna Dashevsky, Aditya R. Das
-
Patent number: 11266799Abstract: A delivery device for a compound including: a housing, vial holding a compound; and a source of propellant, wherein the housing provides an inlet and an outlet for the vial, wherein the inlet is in fluid communication with the source of propellant and is directed against the in-line nasal delivery device compound and the outlet allows for delivery of the compound.Type: GrantFiled: September 9, 2016Date of Patent: March 8, 2022Assignee: Impel Neuropharma, Inc.Inventors: Christopher Fuller, John D. Hoekman, Craig Kohring
-
Patent number: 11191910Abstract: A unit dose container for the containment of an intranasal formulation for use with the POD device.Type: GrantFiled: November 25, 2019Date of Patent: December 7, 2021Assignee: Impel Neuropharma, Inc.Inventors: John D. Hoekman, Alan Brunelle, Craig Kohring, Christopher Fuller
-
Patent number: 11185497Abstract: Methods are provided for acutely treating migraine headache with or without aura. The methods comprise administering to a subject with migraine headache an effective dose of a liquid pharmaceutical composition comprising dihydroergotamine (DHE) or a salt thereof, wherein the dose is administered by an intranasal delivery device that provides, following intranasal administration, (a) a mean peak plasma DHE concentration (Cmax) of at least 750 pg/ml, (b) with a mean time to Cmax (Tmax) of DHE of less than 45 minutes, and (c) a mean plasma AUC0-inf of DHE of at least 2500 pg*hr/ml. Also provided are kits for acutely treating migraine with or without aura in which a liquid pharmaceutical composition comprising DHE or DHE salt is contained within a sealed vial that is attachable to a precision intranasal olfactory delivery device packaged therewith.Type: GrantFiled: October 2, 2020Date of Patent: November 30, 2021Assignee: Impel Neuropharma, Inc.Inventors: John D. Hoekman, Kelsey H. Satterly, Stephen B. Shrewsbury, Scott Youmans, Christopher Fuller
-
Patent number: 11007332Abstract: A nozzle for use in delivering a mixture of aerosol propellant and drug formulation. The nozzle includes a drug product inlet configured to receive a mixture of aerosolized propellant and an intranasal dosage form. The inlet is disposed at the proximal end. A nozzle body is secured to the drug product inlet. Two or more channels are disposed within the body. Two or more orifice apertures are disposed at the distal end of the nozzle.Type: GrantFiled: December 15, 2017Date of Patent: May 18, 2021Assignee: IMPEL NEUROPHARMA, INC.Inventors: John D. Hoekman, Michael Hite, Alan Brunelle, Joel Relethford
-
Patent number: 10940278Abstract: A nozzle for use in delivering a mixture of aerosol propellant and drug formulation. The nozzle includes a drug product inlet configured to receive a mixture of aerosolized propellant and an intranasal dosage form. The inlet is disposed at the proximal end. A nozzle body is secured to the drug product inlet. Two or more channels are disposed within the body. Two or more orifice apertures are disposed at the distal end of the nozzle.Type: GrantFiled: February 6, 2018Date of Patent: March 9, 2021Assignee: IMPEL NEUROPHARMA, INC.Inventors: John D. Hoekman, Michael Hite, Alan Brunelle, Joel Relethford
-
Patent number: 10537692Abstract: A unit dose container for the containment of an intranasal formulation for use with the POD device.Type: GrantFiled: April 28, 2014Date of Patent: January 21, 2020Assignee: Impel Neuropharma, Inc.Inventors: John D. Hoekman, Alan Brunelle, Craig Kohring, Christopher Fuller
-
Patent number: 10507295Abstract: A compound delivery device for delivering a plume derived from a propellant and a drug formulation. The drug formulation is in an intranasal dosage form in the form of powder, suspension, dispersion or liquid. The propelled intranasal dosage form is deposited within the olfactory region of the nasal cavity. The drug deposited within the olfactory region is delivered to the brain avoiding the blood-brain-barrier. Hydrofluoroalkane propellant from a pressurized canister is channeled to a diffuser and drug-containing chamber where the intra-nasal dosage form is aerosolized. The aerosolized intra-nasal dosage form passes through a nozzle thus delivering a plume to the olfactory region of a user's nasal cavity.Type: GrantFiled: October 28, 2016Date of Patent: December 17, 2019Assignee: Impel Neuropharma, Inc.Inventors: John D. Hoekman, Michael Hite, Alan Brunelle, Joel Relethford, Rodney J. Y. Ho
-
Patent number: 9919117Abstract: A nozzle for use in delivering a mixture of aerosol propellant and drug formulation. The nozzle includes a drug product inlet configured to receive a mixture of aerosolized propellant and an intranasal dosage form. The inlet is disposed at the proximal end. A nozzle body is secured to the drug product inlet. Two or more channels are disposed within the body. Two or more orifice apertures are disposed at the distal end of the nozzle.Type: GrantFiled: November 8, 2013Date of Patent: March 20, 2018Assignee: IMPEL NEUROPHARMA INC.Inventors: John D. Hoekman, Michael Hite, Alan Brunelle, Joel Relethford
-
Patent number: 9550036Abstract: A compound delivery device for delivering a plume derived from a propellant and a drug formulation. The drug formulation is in an intranasal dosage form in the form of powder, suspension, dispersion or liquid. The propelled intranasal dosage form is deposited within the olfactory region of the nasal cavity. The drug deposited within the olfactory region is delivered to the brain avoiding the blood-brain-barrier. Hydrofluoroalkane propellant from a pressurized canister is channeled to a diffuser and drug-containing chamber where the intra-nasal dosage form is aerosolized. The aerosolized intra-nasal dosage form passes through a nozzle thus delivering a plume to the olfactory region of a user's nasal cavity.Type: GrantFiled: September 3, 2013Date of Patent: January 24, 2017Assignee: Impel NeuroPharma Inc.Inventors: John D. Hoekman, Michael Hite, Alan Brunelle, Joel Relethford, Rodney J. Y. Ho
-
Publication number: 20160101245Abstract: A unit dose container for the containment of an intranasal formulation for use with the POD device.Type: ApplicationFiled: April 28, 2014Publication date: April 14, 2016Applicant: IMPEL NEUROPHARMA INC.Inventors: John D. Hoekman, Alan Brunelle, Craig Kohring, Christopher Fuller
-
Publication number: 20140083424Abstract: A nozzle for use in delivering a mixture of aerosol propellant and drug formulation. The nozzle includes a drug product inlet configured to receive a mixture of aerosolized propellant and an intranasal dosage form. The inlet is disposed at the proximal end. A nozzle body is secured to the drug product inlet. Two or more channels are disposed within the body. Two or more orifice apertures are disposed at the distal end of the nozzle.Type: ApplicationFiled: November 8, 2013Publication date: March 27, 2014Applicant: Impel NeuroPharma Inc.Inventors: John D. Hoekman, Michael Hite, Alan Brunelle, Joel Relethford
-
Publication number: 20140014104Abstract: A compound delivery device for delivering a plume derived from a propellant and a drug formulation. The drug formulation is in an intranasal dosage form in the form of powder, suspension, dispersion or liquid. The propelled intranasal dosage form is deposited within the olfactory region of the nasal cavity. The drug deposited within the olfactory region is delivered to the brain avoiding the blood-brain-barrier. Hydrofluoroalkane propellant from a pressurized canister is channeled to a diffuser and drug-containing chamber where the intra-nasal dosage form is aerosolized. The aerosolized intra-nasal dosage form passes through a nozzle thus delivering a plume to the olfactory region of a user's nasal cavity.Type: ApplicationFiled: September 3, 2013Publication date: January 16, 2014Applicant: Impel NeuroPharma Inc.Inventors: John D. Hoekman, Michael Hite, Alan Brunelle, Joel Relethford, Rodney J.Y. Ho